BindingDB logo
myBDB logout

Patent code US10870639

Compile Data Set for Download or QSAR
Found 27 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)		LigandTarget/Host
Links		Ligand
Links		Trg + Lig
Links		Ki
nM		ΔG°
kJ/mole		IC50
nM		Kd
nM		EC50/IC50
nM		koff
s-1		kon
M-1s-1		pHTemp
°C
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476704
PNG
( (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-di...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(CO)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-17-13-36(14-18(2)33-17)15-20-7-22(21-4-5-21)10-23(8-20)34-29-32-12-26(30)28(35-29)25-11-31-27-9-19(16-37)3-6-24(25)27/h3,6-12,17-18,21,31,33,37H,4-5,13-16H2,1-2H3,(H,32,34,35)/t17-,18+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476709
PNG
(2-((5-chloro-4-(6-methyl-1H-indole-3-yl)pyrimidine...)
Show SMILES C[C@H]1CN(Cc2cc(cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)c2O)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-16-4-7-22-23(11-31-25(22)8-16)27-24(30)12-32-29(35-27)34-26-10-20(19-5-6-19)9-21(28(26)37)15-36-13-17(2)33-18(3)14-36/h4,7-12,17-19,31,33,37H,5-6,13-15H2,1-3H3,(H,32,34,35)/t17-,18+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.400n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476704
PNG
( (3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-di...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(CO)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-17-13-36(14-18(2)33-17)15-20-7-22(21-4-5-21)10-23(8-20)34-29-32-12-26(30)28(35-29)25-11-31-27-9-19(16-37)3-6-24(25)27/h3,6-12,17-18,21,31,33,37H,4-5,13-16H2,1-2H3,(H,32,34,35)/t17-,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 0.5n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476700
PNG
(5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethyl...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

MCE
PC cid
PC sid
UniChem
US Patent
n/an/a 1.10n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476702
PNG
(N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(F)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33FN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.20n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476695
PNG
(5-chloro-4-(6-chloro-1H-indole-3-yl)-N-(3-cyclopro...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(Cl)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C28H30Cl2N6/c1-16-13-36(14-17(2)33-16)15-18-7-20(19-3-4-19)9-22(8-18)34-28-32-12-25(30)27(35-28)24-11-31-26-10-21(29)5-6-23(24)26/h5-12,16-17,19,31,33H,3-4,13-15H2,1-2H3,(H,32,34,35)/t16-,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.5n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476711
PNG
( ((2R,6R)-4-(3-((5-chloro-4-(6-methyl-1H-indole-3-...)
Show SMILES C[C@@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@H](CO)N1
Show InChI InChI=1S/C29H33ClN6O/c1-17-3-6-24-25(11-31-27(24)7-17)28-26(30)12-32-29(35-28)34-22-9-19(8-21(10-22)20-4-5-20)14-36-13-18(2)33-23(15-36)16-37/h3,6-12,18,20,23,31,33,37H,4-5,13-16H2,1-2H3,(H,32,34,35)/t18-,23-/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.5n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476700
PNG
(5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethyl...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

MCE
PC cid
PC sid
UniChem
US Patent
n/an/a 1.80n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476699
PNG
((R)-5-chloro-N-(3-cyclopropyl-5-((3-methylpiperazi...)
Show SMILES C[C@@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4ccccc34)cc(c2)C2CC2)CCN1
Show InChI InChI=1S/C27H29ClN6/c1-17-15-34(9-8-29-17)16-18-10-20(19-6-7-19)12-21(11-18)32-27-31-14-24(28)26(33-27)23-13-30-25-5-3-2-4-22(23)25/h2-5,10-14,17,19,29-30H,6-9,15-16H2,1H3,(H,31,32,33)/t17-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.80n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476695
PNG
(5-chloro-4-(6-chloro-1H-indole-3-yl)-N-(3-cyclopro...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(Cl)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C28H30Cl2N6/c1-16-13-36(14-17(2)33-16)15-18-7-20(19-3-4-19)9-22(8-18)34-28-32-12-25(30)27(35-28)24-11-31-26-10-21(29)5-6-23(24)26/h5-12,16-17,19,31,33H,3-4,13-15H2,1-2H3,(H,32,34,35)/t16-,17+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 1.90n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476711
PNG
( ((2R,6R)-4-(3-((5-chloro-4-(6-methyl-1H-indole-3-...)
Show SMILES C[C@@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@H](CO)N1
Show InChI InChI=1S/C29H33ClN6O/c1-17-3-6-24-25(11-31-27(24)7-17)28-26(30)12-32-29(35-28)34-22-9-19(8-21(10-22)20-4-5-20)14-36-13-18(2)33-23(15-36)16-37/h3,6-12,18,20,23,31,33,37H,4-5,13-16H2,1-2H3,(H,32,34,35)/t18-,23-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.30n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476710
PNG
((R)-5-chloro-N-(3-cyclopropyl-5-((3,3,5-trimethylp...)
Show SMILES C[C@@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)CC(C)(C)N1
Show InChI InChI=1S/C30H35ClN6/c1-18-5-8-24-25(13-32-27(24)9-18)28-26(31)14-33-29(35-28)34-23-11-20(10-22(12-23)21-6-7-21)16-37-15-19(2)36-30(3,4)17-37/h5,8-14,19,21,32,36H,6-7,15-17H2,1-4H3,(H,33,34,35)/t19-/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.30n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476708
PNG
(3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dime...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4c(O)c(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-16-4-7-23-24(11-31-27(23)28(16)37)26-25(30)12-32-29(35-26)34-22-9-19(8-21(10-22)20-5-6-20)15-36-13-17(2)33-18(3)14-36/h4,7-12,17-18,20,31,33,37H,5-6,13-15H2,1-3H3,(H,32,34,35)/t17-,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.40n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476702
PNG
(N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(F)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33FN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 2.5n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476701
PNG
(US10870639, Example 10 | US11292786, Example 10 | ...)
Show SMILES CC1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)CC(C)N1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3.60n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476697
PNG
(2-((2R,6S)-4-(3-((5-chloro-4-(1H-indole-3-yl)pyrim...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4ccccc34)cc(c2)C2CC2)C[C@@H](C)N1CCO
Show InChI InChI=1S/C30H35ClN6O/c1-19-16-36(17-20(2)37(19)9-10-38)18-21-11-23(22-7-8-22)13-24(12-21)34-30-33-15-27(31)29(35-30)26-14-32-28-6-4-3-5-25(26)28/h3-6,11-15,19-20,22,32,38H,7-10,16-18H2,1-2H3,(H,33,34,35)/t19-,20+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3.60n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476706
PNG
(3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dime...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)c(O)cc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-16-6-26-23(10-27(16)37)24(11-31-26)28-25(30)12-32-29(35-28)34-22-8-19(7-21(9-22)20-4-5-20)15-36-13-17(2)33-18(3)14-36/h6-12,17-18,20,31,33,37H,4-5,13-15H2,1-3H3,(H,32,34,35)/t17-,18+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 3.70n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476712
PNG
((2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indole-3-yl...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1O
Show InChI InChI=1S/C29H33ClN6O/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(34-28)33-23-10-20(9-22(11-23)21-5-6-21)16-35-14-18(2)36(37)19(3)15-35/h4,7-13,18-19,21,31,37H,5-6,14-16H2,1-3H3,(H,32,33,34)/t18-,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 6.90n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476698
PNG
(2-((2R,6S)-4-(3-((5-chloro-4-(6-methyl-1H-indole-3...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1CCO
Show InChI InChI=1S/C31H37ClN6O/c1-19-4-7-26-27(14-33-29(26)10-19)30-28(32)15-34-31(36-30)35-25-12-22(11-24(13-25)23-5-6-23)18-37-16-20(2)38(8-9-39)21(3)17-37/h4,7,10-15,20-21,23,33,39H,5-6,8-9,16-18H2,1-3H3,(H,34,35,36)/t20-,21+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 7.20n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476696
PNG
(2-((2R,6S)-4-(3-((5-chloro-4-(6-fluoro-1H-indole-3...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(F)ccc34)cc(c2)C2CC2)C[C@@H](C)N1CCO
Show InChI InChI=1S/C30H34ClFN6O/c1-18-15-37(16-19(2)38(18)7-8-39)17-20-9-22(21-3-4-21)11-24(10-20)35-30-34-14-27(31)29(36-30)26-13-33-28-12-23(32)5-6-25(26)28/h5-6,9-14,18-19,21,33,39H,3-4,7-8,15-17H2,1-2H3,(H,34,35,36)/t18-,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 8.10n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476703
PNG
(N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(C)c(n3)-c3c[nH]c4ccccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H34N6/c1-18-13-31-29(34-28(18)26-14-30-27-7-5-4-6-25(26)27)33-24-11-21(10-23(12-24)22-8-9-22)17-35-15-19(2)32-20(3)16-35/h4-7,10-14,19-20,22,30,32H,8-9,15-17H2,1-3H3,(H,31,33,34)/t19-,20+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 8.70n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476705
PNG
(5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethyl...)
Show SMILES COc1cc2c(c[nH]c2cc1C)-c1nc(Nc2cc(CN3C[C@H](C)N[C@H](C)C3)cc(c2)C2CC2)ncc1Cl
Show InChI InChI=1S/C30H35ClN6O/c1-17-7-27-24(11-28(17)38-4)25(12-32-27)29-26(31)13-33-30(36-29)35-23-9-20(8-22(10-23)21-5-6-21)16-37-14-18(2)34-19(3)15-37/h7-13,18-19,21,32,34H,5-6,14-16H2,1-4H3,(H,33,35,36)/t18-,19+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 9.5n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476706
PNG
(3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dime...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)c(O)cc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-16-6-26-23(10-27(16)37)24(11-31-26)28-25(30)12-32-29(35-28)34-22-8-19(7-21(9-22)20-4-5-20)15-36-13-17(2)33-18(3)14-36/h6-12,17-18,20,31,33,37H,4-5,13-15H2,1-3H3,(H,32,34,35)/t17-,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476710
PNG
((R)-5-chloro-N-(3-cyclopropyl-5-((3,3,5-trimethylp...)
Show SMILES C[C@@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)CC(C)(C)N1
Show InChI InChI=1S/C30H35ClN6/c1-18-5-8-24-25(13-32-27(24)9-18)28-26(31)14-33-29(35-28)34-23-11-20(10-22(12-23)21-6-7-21)16-37-15-19(2)36-30(3,4)17-37/h5,8-14,19,21,32,36H,6-7,15-17H2,1-4H3,(H,33,34,35)/t19-/m1/s1
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 20n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476707
PNG
(3-(5-chloro-2-((3-cyclopropyl-5-(((3R,5S)-3,5-dime...)
Show SMILES C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)C3C(=O)Nc4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-16-4-7-23-25(8-16)34-28(37)26(23)27-24(30)12-31-29(35-27)33-22-10-19(9-21(11-22)20-5-6-20)15-36-13-17(2)32-18(3)14-36/h4,7-12,17-18,20,26,32H,5-6,13-15H2,1-3H3,(H,34,37)(H,31,33,35)/t17-,18+,26?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a>50n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476705
PNG
(5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethyl...)
Show SMILES COc1cc2c(c[nH]c2cc1C)-c1nc(Nc2cc(CN3C[C@H](C)N[C@H](C)C3)cc(c2)C2CC2)ncc1Cl
Show InChI InChI=1S/C30H35ClN6O/c1-17-7-27-24(11-28(17)38-4)25(12-32-27)29-26(31)13-33-30(36-29)35-23-9-20(8-22(10-23)21-5-6-21)16-37-14-18(2)34-19(3)15-37/h7-13,18-19,21,32,34H,5-6,14-16H2,1-4H3,(H,33,35,36)/t18-,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a>50n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
Dimer of Receptor-type tyrosine-protein kinase FLT3


(Homo sapiens (Human))		BDBM476709
PNG
(2-((5-chloro-4-(6-methyl-1H-indole-3-yl)pyrimidine...)
Show SMILES C[C@H]1CN(Cc2cc(cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)c2O)C2CC2)C[C@@H](C)N1
Show InChI InChI=1S/C29H33ClN6O/c1-16-4-7-22-23(11-31-25(22)8-16)27-24(30)12-32-29(35-27)34-26-10-20(19-5-6-19)9-21(28(26)37)15-36-13-17(2)33-18(3)14-36/h4,7-12,17-19,31,33,37H,5-6,13-15H2,1-3H3,(H,32,34,35)/t17-,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a>50n/an/an/an/an/an/a



HANMI PHARM. CO.. LTD.

US Patent


Assay Description
The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...

US Patent US10870639 (2020)


BindingDB Entry DOI: 10.7270/Q20G3P70
More data for this
Ligand-Target Pair
* indicates data uncertainty>20%